Haleon Pakistan Limited, the local subsidiary of the global consumer healthcare group formerly known as GlaxoSmithKline Consumer Healthcare, has posted a strong financial performance during the first nine months of calendar year 2025, reflecting resilient demand and improved operational efficiency in Pakistan’s consumer health sector. The company recorded net sales of around Rs 32.2 billion, marking a year-on-year increase of approximately 17 percent. This growth was driven by a combination of moderate price adjustments and healthy volume expansion, indicating sustained consumer demand despite broader economic pressures.
Read More: Growth Momentum Stalls at Symmetry Group Following a Strong 2025 Performance
Profitability improved significantly over the period as gross profit rose sharply, supported by easing raw material costs and a higher share of locally manufactured products. Gross margins expanded to about 38 percent compared to the previous year, highlighting the benefits of localisation and better cost management. Lower exchange losses and reduced finance costs further strengthened earnings. As a result, net profit climbed to nearly Rs 4.6 billion, representing growth of more than 40 percent year on year, while earnings per share increased accordingly.
Haleon Pakistan’s performance was underpinned by broad-based growth across its portfolio. The fast-moving consumer goods and over-the-counter segments both delivered solid double-digit growth. Leading brands such as Panadol, CAC-1000 and Sensodyne continued to dominate their respective categories, contributing a major share of overall revenues. Continued brand investment and selective product innovation also supported sales momentum.
Looking ahead, the company remains well positioned for sustainable growth, supported by strong brand equity, an expanding consumer healthcare market and ongoing investments in local manufacturing capacity. Planned expansion at its Jamshoro facility is expected to further enhance supply efficiency and margins over the medium term. While regulatory changes, currency volatility and input cost fluctuations remain key risks, Haleon Pakistan’s improved profitability, diversified product base and focus on operational efficiency suggest a positive outlook for the coming periods.
